XtalPi and Gan & Lee Announce Global Strategic Collaboration on AI-Powered Peptide Drug Discovery for Metabolic Diseases

XtalPi (Stock Code:2228.HK) announced today, leading in the field of metabolic disease treatment in ChinaMilitary EnterprisesGan&Lee Pharmaceuticals(Stock Code: 603087.SH) Announces Global Strategic Collaboration and Platform Licensing for AI-Powered Peptide Innovation Drug DevelopmentAgreement. According to the terms of cooperation, XtalPi will receive payments based on the pipeline progress.Platform licensing fees, upfront payments, clinical and commercial milestone payments, and revenue sharing from pipeline re-licensing。This collaboration represents another commercial milestone for XtalPi in the field of AI-driven peptide research and development, marking XtalPi's AI-powered peptide drug discovery platform as having undergone extensive...After successful verification, its technical strength and commercial value have gained high recognition from top pharmaceutical companies in the industry. The two companies will deeply collaborate in AI-powered peptide drug innovation and overseas market expansion, making comprehensive arrangements in new targets, new mechanisms, and new therapies, while driving the continuous technological upgrade and value realization of XtalPi's AI peptide R&D platform. Together, they are advancing towards the strategic vision of "defining the next generation of peptide therapies for metabolic diseases and benefiting patients worldwide."

XtalPi Chief Innovation Officer Lipeng Lai (left)

Attended the signing ceremony on behalf of the company with Gan&Lee Pharmaceuticals Chairman and CEO Wei Chen (right)

According to the cooperation agreement, Gan&Lee Pharmaceuticals will rely on XtalPi's self-developed AI peptide R&D proprietary platform PepiX™, focusing on core therapeutic needs in the field of metabolic diseases to accelerate the discovery and development process of novel peptide drugs. XtalPi will utilize AI generative peptide design, stability enhancement, modification strategy optimization, drug-likeness prediction, and other full-chain technologies. “AI + Wet Lab” Technical capabilities to precisely design, efficiently screen, and optimize the performance of candidate drugs, covering key stages from molecular design to the identification of preclinical candidate compounds, thereby significantly shortening the R&D cycle and enhancing the efficiency and success rate of candidate drug development.

The two parties will also form a strategic collaboration team to deeply integrate Gan&Lee Pharmaceuticals' core resources in the field of metabolic disease research and XtalPi's AI peptide R&D technology platform through a closed-loop ecosystem of "AI-driven R&D - clinical translation - commercialization implementation." Relying on Gan&Lee Pharmaceuticals' mature peptide production and sales network and XtalPi's partner matrix spanning across China, Europe, and the U.S., they will accelerate the commercial transformation of new drug pipelines and continuously promote the platform upgrade of XtalPi.

As a pioneer in China's AI-driven peptide pharmaceuticals sector, XtalPi has long focused on the deep integration of artificial intelligence, automated synthesis technology, and peptide drug research and development, establishing an integrated peptide R&D platform.PepiX™It covers technical capabilities such as de novo molecular design, automated synthesis, and sequence optimization for high-throughput library screening, which can significantly improve key drug attributes like molecular stability, half-life, and oral bioavailability in a short period. This AI peptide R&D platform has been successfully validated in multiple internal and external projects, effectively designing innovative peptide molecules with strong competitive advantages and developability, significantly shortening the R&D cycle and increasing the return on innovation.

This collaboration represents a precise alignment of the industry needs and technical strengths of both parties — Gan&Lee Pharmaceuticals has achieved leading results in the field of endocrine and metabolic diseases, with nearly 30 years of deep cultivation. Meanwhile, its Beijing headquarters boasts a 3.5-ton capacity for active pharmaceutical ingredients and a commercial network covering 45,000 hospitals. XtalPi's AI peptide R&D platform holds unique advantages in novel target discovery and rapid compound screening, enabling efficient synergy with Gan&Lee Pharmaceuticals. This partnership will help Gan&Lee enrich its differentiated pipeline innovation while continuously driving the optimization and upgrading of XtalPi’s AI R&D platform, creating value for innovative partners and investors.

Leveraging the cutting-edge R&D practices of industry leaders such as Gan&Lee Pharmaceuticals, along with globally leading AI-driven pharmaceutical business collaborations, XtalPi is actively expanding industrial-level partnerships for its AI-powered peptide R&D platform.This move will further enhance the scarce value and integration advantages of XtalPi's multi-dimensional AI drug discovery platform, which covers peptides, antibodies, small molecules, ADCs, and molecular glues, accelerating the efficient transformation of its technical barriers and scale benefits into commercial returns.

Dr. Lipeng Lai, Chief Innovation Officer of XtalPi, said:"This collaboration with Gan&Lee Pharmaceuticals, a leading company in the metabolic disease field, marks XtalPi's AI peptide R&D platform entering a fully industrial-level empowerment phase after years of deep cultivation and extensive practical validation. We will closely partner with Gan&Lee to leverage both teams' profound expertise in peptide design and development, enhancing the differentiation advantages of candidate drugs from the outset, building an end-to-end efficient development loop, and jointly advancing the paradigm shift in peptide drug R&D. We look forward to XtalPi."ThePepiX™ AI Peptide R&D Platform Accelerates Breakthrough Peptide Therapies to Benefit Patients Worldwide, Creating New Clinical Value for Metabolic Disease Treatment.

Dr. Wei Chen, Chairman and CEO of Gan&Lee Pharmaceuticals, stated:"We have always been focused on the application of cutting-edge technologies in drug development, and AI technology is leading a transformative wave in the biopharmaceuticals industry. This collaboration with XtalPi is an important step in implementing our innovation strategy and promoting integrated development, offering us new perspectives and technical pathways for research. We look forward to leveraging AI to further enhance R&D efficiency, accelerate the development of high-quality peptide drugs, address unmet clinical needs in the treatment of endocrine and metabolic diseases, and provide more innovative, high-quality treatment options for patients worldwide."

This strategic cooperation marks a significant leap in the collaboration scale of XtalPi's AI peptide R&D platform, further solidifying its leading position in the field of AI-driven large molecule drug innovation. In the future, building on this cooperation as a starting point, the AI + automated experimental platform and Gan&Lee Pharmaceuticals' industry expertise will continue to deepen the integration and innovation of AI technology with peptide drug R&D. This will accelerate breakthroughs in next-generation peptide therapies, lead the global upgrade of peptide drug R&D paradigms, and work together with industry partners to build an open and win-win innovative ecosystem, contributing more Chinese wisdom and strength to the global prevention and treatment of metabolic diseases.

● CloseYuGan&Lee Pharmaceuticals●

Gan&Lee Pharmaceuticals (Abbreviation: Gan&Lee Pharmaceuticals, Stock Code: 603087.SH) is China's first high-tech biopharmaceutical company to successfully achieve the industrial production of recombinant insulin analogs and is a domestic leader in the field of endocrine and metabolic treatment. The company has developed a complete portfolio of insulin products, comprehensively covering second-generation and third-generation insulin, including long-acting, rapid-acting, and premixed insulin, with six core products currently available. In 2024, the company ranked first among selected enterprises for its insulin analog procurement agreement volume and successfully passed the GMP inspection by the European Medicines Agency (EMA), gaining international recognition for its production quality management system. Rooted in China and with a global perspective, Gan&Lee Pharmaceuticals is always committed to providing higher-quality medicines and services to patients worldwide.